- Home
- DHF vs IPHA Comparison
DHF vs IPHA Comparison
Compare DHF & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DHF | IPHA |
|---|---|---|
| Founded | 1998 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 174.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | DHF | IPHA |
|---|---|---|
| Price | $2.49 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 451.1K | 27.0K |
| Earning Date | 01-01-0001 | 09-17-2025 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.06 | $1.60 |
| 52 Week High | $2.39 | $2.63 |
Technical Indicators
Market Signals| Indicator | DHF | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 45.97 | 50.72 |
| Support Level | $2.46 | $1.70 |
| Resistance Level | $2.49 | $1.83 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 41.67 | 62.90 |
Price Performance
Historical ComparisonAbout DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.